First Allied Advisory Services’s ImmunoCellular Therapeutics, Ltd. IMUC Stock Holding History

First Allied Advisory Services’s Portfolio IMUC Stock Details IMUC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-40,000	Closed	-$8K	–	1245
2018 Q3	$8K	Hold	40,000	–	–	﹤0.01%	1177
2018 Q2	$10K	Hold	40,000	–	–	﹤0.01%	1143
2018 Q1	$10K	Buy	+40,000	New	+$11K	﹤0.01%	1162
2015 Q4	–	Sell	-1,125	Closed	-$19K	–	1180
2015 Q3	$19K	Hold	1,125	–	–	﹤0.01%	1039
2015 Q2	$21K	Hold	1,125	–	–	﹤0.01%	1133
2015 Q1	$22K	Hold	1,125	–	–	﹤0.01%	1060
2014 Q4	$33K	Hold	1,125	–	–	﹤0.01%	1014
2014 Q3	$40K	Hold	1,125	–	–	﹤0.01%	1015
2014 Q2	$50K	Hold	1,125	–	–	﹤0.01%	964
2014 Q1	$55K	Hold	1,125	–	–	﹤0.01%	982
2013 Q4	$42K	Buy	1,125 +125	+13%	+$11.8K	﹤0.01%	931
2013 Q3	$103K	Hold	1,000	–	–	0.01%	951
2013 Q2	$78K	Buy	+1,000	New	+$95.8K	0.01%	916

Other funds holding IMUC

Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

First Allied Advisory Services's IMUC Position: Q4 2018 in Review

First Allied Advisory Services sold out of ImmunoCellular Therapeutics, Ltd. (IMUC) in Q4 2018, closing a stake of 40,000 shares — an estimated $8K sold.

First Allied Advisory Services first reported a position in IMUC in Q2 2013 and held it in 13 quarters. The position peaked at $103K in Q3 2013. 3 funds tracked by Wall St. Rank hold IMUC as of Q4 2018.

First Allied Advisory Services reported no remaining ImmunoCellular Therapeutics, Ltd. position as of Q4 2018 after selling out during the quarter.
First Allied Advisory Services sold 40,000 ImmunoCellular Therapeutics, Ltd. shares in Q4 2018, an estimated $8K.
First Allied Advisory Services first reported a position in ImmunoCellular Therapeutics, Ltd. in Q2 2013 and held it in 13 quarters.
First Allied Advisory Services's ImmunoCellular Therapeutics, Ltd. position peaked at $103K in Q3 2013.
3 funds tracked by Wall St. Rank held ImmunoCellular Therapeutics, Ltd. as of Q4 2018.

Based on First Allied Advisory Services's 13F filing for Q4 2018, filed 15 Feb 2019.